Name | Number of supported studies | Average coverage | |
---|---|---|---|
ciliated cell | 16 studies | 47% ± 17% | |
epithelial cell | 16 studies | 43% ± 21% | |
secretory cell | 10 studies | 50% ± 22% | |
type II pneumocyte | 9 studies | 78% ± 23% | |
club cell | 9 studies | 57% ± 21% | |
goblet cell | 9 studies | 41% ± 18% | |
type I pneumocyte | 8 studies | 46% ± 17% | |
basal cell | 8 studies | 28% ± 13% | |
respiratory goblet cell | 7 studies | 73% ± 22% | |
ionocyte | 6 studies | 58% ± 10% | |
kidney loop of Henle epithelial cell | 5 studies | 49% ± 22% | |
renal alpha-intercalated cell | 5 studies | 55% ± 12% | |
deuterosomal cell | 4 studies | 70% ± 8% | |
transit amplifying cell | 4 studies | 20% ± 2% | |
luminal hormone-sensing cell of mammary gland | 4 studies | 32% ± 6% | |
duct epithelial cell | 3 studies | 70% ± 11% | |
squamous epithelial cell | 3 studies | 68% ± 13% | |
kidney distal convoluted tubule epithelial cell | 3 studies | 65% ± 7% | |
renal principal cell | 3 studies | 71% ± 8% | |
acinar cell | 3 studies | 43% ± 30% | |
mucus secreting cell | 3 studies | 45% ± 29% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 100% | 10433.98 | 328 / 328 | 86% | 468.94 | 153 / 178 |
lung | 99% | 21015.21 | 570 / 578 | 73% | 335.63 | 847 / 1155 |
stomach | 99% | 42587.70 | 355 / 359 | 69% | 209.57 | 198 / 286 |
uterus | 89% | 2685.27 | 152 / 170 | 64% | 208.35 | 292 / 459 |
esophagus | 93% | 5803.57 | 1346 / 1445 | 57% | 178.80 | 104 / 183 |
bladder | 95% | 2296.62 | 20 / 21 | 55% | 149.15 | 275 / 504 |
breast | 66% | 4650.70 | 302 / 459 | 84% | 388.51 | 938 / 1118 |
intestine | 79% | 5970.47 | 766 / 966 | 64% | 164.98 | 339 / 527 |
kidney | 100% | 21221.58 | 89 / 89 | 35% | 53.47 | 313 / 901 |
thymus | 94% | 3705.48 | 616 / 653 | 39% | 52.48 | 237 / 605 |
ovary | 26% | 386.72 | 46 / 180 | 94% | 388.00 | 403 / 430 |
ureter | 0% | 0 | 0 / 0 | 100% | 188.24 | 1 / 1 |
prostate | 88% | 2776.35 | 215 / 245 | 6% | 9.83 | 29 / 502 |
blood vessel | 66% | 1118.20 | 875 / 1335 | 0% | 0 | 0 / 0 |
adipose | 37% | 531.97 | 450 / 1204 | 0% | 0 | 0 / 0 |
skin | 35% | 587.82 | 631 / 1809 | 1% | 0.78 | 4 / 472 |
tonsil | 0% | 0 | 0 / 0 | 36% | 47.56 | 16 / 45 |
adrenal gland | 7% | 87.58 | 18 / 258 | 0% | 0.66 | 1 / 230 |
liver | 2% | 18.29 | 4 / 226 | 5% | 11.22 | 21 / 406 |
heart | 3% | 30.18 | 23 / 861 | 0% | 0 | 0 / 0 |
spleen | 2% | 28.46 | 6 / 241 | 0% | 0 | 0 / 0 |
brain | 1% | 9.37 | 22 / 2642 | 0% | 0 | 0 / 705 |
muscle | 0% | 5.28 | 4 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 9.15 | 2 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0030330 | Biological process | DNA damage response, signal transduction by p53 class mediator |
GO_1902166 | Biological process | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator |
GO_0010944 | Biological process | negative regulation of transcription by competitive promoter binding |
GO_0033629 | Biological process | negative regulation of cell adhesion mediated by integrin |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0006977 | Biological process | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest |
GO_0016324 | Cellular component | apical plasma membrane |
GO_0005615 | Cellular component | extracellular space |
GO_0005796 | Cellular component | Golgi lumen |
GO_0070062 | Cellular component | extracellular exosome |
GO_0000785 | Cellular component | chromatin |
GO_0031982 | Cellular component | vesicle |
GO_0005886 | Cellular component | plasma membrane |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0005515 | Molecular function | protein binding |
GO_0003712 | Molecular function | transcription coregulator activity |
GO_0002039 | Molecular function | p53 binding |
Gene name | MUC1 |
Protein name | MUC1 isoform M11 MUC1 isoform T3 MUC1 isoform M16 Mucin short variant S1 Mucin short variant SV8 MUC1 isoform J15 MUC1 isoform J26 (Mucin 1, cell surface associated) Mucin 1, cell surface associated (Mucin short variant SV10) Mucin short variant SV2 MUC1 isoform T6 Mucin 1, cell surface associated Mucin short variant SV7 MUC1 isoform T2 MUC1 isoform M15 MUC1 isoform M13 Mucin-1 Mucin short variant SV3 Mucin short variant PC1 Mucin short variant E1 Mucin-1 (MUC-1) (Breast carcinoma-associated antigen DF3) (Cancer antigen 15-3) (CA 15-3) (Carcinoma-associated mucin) (Episialin) (H23AG) (Krebs von den Lungen-6) (KL-6) (PEMT) (Peanut-reactive urinary mucin) (PUM) (Polymorphic epithelial mucin) (PEM) (Tumor-associated epithelial membrane antigen) (EMA) (Tumor-associated mucin) (CD antigen CD227) [Cleaved into: Mucin-1 subunit alpha (MUC1-NT) (MUC1-alpha); Mucin-1 subunit beta (MUC1-beta) (MUC1-CT)] MUC1 isoform T5 MUC1 isoform T4 Mucin short variant SV9 Mucin MUC1 isoform T1 MUC1 isoform M1 MUC1 isoform M9 MUC1 isoform M14 Mucin short variant PC2 MUC1 isoform M10 (Mucin 1, cell surface associated) MUC1 isoform J1 (MUC1 isoform J16) (MUC1 isoform J18) (MUC1 isoform J2) (MUC1 isoform J4) (MUC1 isoform J5) (MUC1 isoform J6) (MUC1 isoform J7) (MUC1 isoform J9) MUC1 isoform T13 MUC1 isoform SV7-LSP Mucin short variant SV1 MUC1 isoform M4 MUC1 isoform T12 MUC1 isoform J24 MUC1 isoform M5 |
Synonyms | PUM |
Description | FUNCTION: The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack.; FUNCTION: The beta subunit contains a C-terminal domain which is involved in cell signaling, through phosphorylations and protein-protein interactions. Modulates signaling in ERK, SRC and NF-kappa-B pathways. In activated T-cells, influences directly or indirectly the Ras/MAPK pathway. Promotes tumor progression. Regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. Binds, together with KLF4, the PE21 promoter element of TP53 and represses TP53 activity. |
Accessions | A0A087WTR1 A0A087X061 B6ECA2 ENST00000368392.7 [P15941-11] ENST00000337604.6 [P15941-8] ENST00000620103.4 ENST00000343256.9 [P15941-10] ENST00000438413.5 A5YRU6 A0A0C4DGW3 A0A0A0MRB3 B6EC89 ENST00000342482.8 [P15941-16] A6ZIE2 ENST00000457295.6 A0A087WVJ0 ENST00000368396.8 [P15941-12] Q7Z551 B6EC96 A6ZIF0 Q7Z537 A0A087WWM2 A5YRU8 A6ZIE5 ENST00000462215.5 A0A087X0L2 A6ZID8 Q14877 ENST00000485118.5 B6ECA3 Q7Z542 ENST00000368398.7 [P15941-6] A5YRV2 A6ZIE9 A6ZIE7 A5YRV3 A5YRU4 A5YRU0 A0A087WZZ6 Q7Z539 ENST00000614519.4 A6ZIE4 Q7Z543 Q7Z549 B6ECB1 A6ZID7 ENST00000368393.7 [P15941-13] ENST00000471283.5 ENST00000498431.5 A6ZID5 Q7Z536 B1AVQ7 Q7Z541 A6ZIE6 ENST00000610468.4 A5YRU7 Q7Z545 A6ZID6 P15941 Q7Z544 A5YRV4 A6ZIF1 A5YRU5 A5YRU2 A0A0A0MSH4 B6ECB3 ENST00000368390.7 [P15941-7] Q7Z546 Q7Z538 B6ECB2 A5YRU3 B6ECA4 ENST00000615517.4 A6ZIE8 B6ECB0 A6ZIE3 B6ECB5 A6ZIE1 ENST00000467134.5 A6ZID4 A5YRU9 Q7Z540 ENST00000462317.5 A5YRV0 B6ECA9 A5YRU1 ENST00000610359.4 A0A087WZI8 ENST00000368389.6 [P15941-9] ENST00000338684.9 |